721 related articles for article (PubMed ID: 22717676)
61. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.
Zuco V; De Cesare M; Cincinelli R; Nannei R; Pisano C; Zaffaroni N; Zunino F
PLoS One; 2011; 6(12):e29085. PubMed ID: 22194993
[TBL] [Abstract][Full Text] [Related]
62. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
63. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
64. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
65. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
66. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Yu C; Friday BB; Yang L; Atadja P; Wigle D; Sarkaria J; Adjei AA
Neuro Oncol; 2008 Jun; 10(3):309-19. PubMed ID: 18445700
[TBL] [Abstract][Full Text] [Related]
67. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
68. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
69. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
70. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
71. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
72. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
73. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
[TBL] [Abstract][Full Text] [Related]
74. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
[TBL] [Abstract][Full Text] [Related]
75. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH
Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375
[TBL] [Abstract][Full Text] [Related]
76. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
77. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
Kahana S; Finniss S; Cazacu S; Xiang C; Lee HK; Brodie S; Goldstein RS; Roitman V; Slavin S; Mikkelsen T; Brodie C
Cell Signal; 2011 Aug; 23(8):1348-57. PubMed ID: 21440622
[TBL] [Abstract][Full Text] [Related]
78. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
[TBL] [Abstract][Full Text] [Related]
79. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
[TBL] [Abstract][Full Text] [Related]
80. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]